Morningstar's Take
MSB
- mce-anchorAnalyst
Column 1 Column 2 Column 3 0 Price 04-07-2015 Fair Value Estimate Uncertainty 1 3.28 AUD 7 AUD Very High 2 3 Consider Buy Consider Sell Economic Moat 4 3.5 AUD 12.25 AUD None 5 6 Stewardship Rating 7 Standard
Column 1 Column 2 0 1 Bulls Say 2 3 • First-mover advantage in a potentially large market. 4 5 • Strong balance sheet. 6 7 • Broad late-stage pipeline withfive phase III clinical trials underway.
Column 1 Column 2 0 1 Bears Say 2 3 • Mesoblast is yet to develop a product that has been commercialised. 4 5 • A new class of therapy not yet fully understood or proven, so arguably there is a higher-than-average risk that harmful side effects could emerge. 6 7 • Industrial scale manufacturing may present challenges.
analysis report, page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 69437 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 19999 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |